AstraZeneca bags CDSCO nod to import, market Andexanet Alfa in India
Bangalore: AstraZeneca Pharma India Ltd., has announced that it has received approval from Central Drugs Standard Control Organisation (CDSCO) in India for the import and marketing of Andexanet Alfa.
This ground-breaking treatment addresses life-threatening or refractory bleeding associated with the use of Factor Xa (FXa) inhibitors.
FXa inhibitors are increasingly employed for preventing and treating thrombotic events, such as deep vein thrombosis and pulmonary embolism, as well as in patients at high risk of stroke due to atrial fibrillation.
While these medications effectively prevent unwanted clot formation, they also elevate the risk of major bleeding, which can be life-threatening, said Dr Sanjeev Panchal, Country President and Managing Director, AstraZeneca India.
Read also: AstraZeneca Voydeya approved in Japan for paroxysmal nocturnal haemoglobinuria
AstraZeneca India was established in 1979 and is headquartered at Bengaluru, Karnataka. AstraZeneca Pharma India Limited (AZPIL) is the operating company and covers manufacturing, sales and marketing activities of the company in India.
Read also: AstraZeneca Gets CDSCO Panel Nod to Study anti-cancer drug Dato-DXd and Durvalumab
Next Story
